or Try an Advanced Search...

    Technical Analysis for RLMD - Relmada Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 2.78 -2.46% -0.07
    RLMD closed down 4.36 percent on Wednesday, November 20, 2024, on 87 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical RLMD trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness -2.46%
    Below Lower BB Weakness -2.46%
    Lower Bollinger Band Touch Weakness -2.46%
    Oversold Stochastic Weakness -2.46%
    Lower Bollinger Band Walk Weakness -6.71%
    Oversold Stochastic Weakness -6.71%
    Lower Bollinger Band Walk Weakness -7.95%
    Inside Day Range Contraction -7.95%
    Lower Bollinger Band Touch Weakness -7.95%
    Oversold Stochastic Weakness -7.95%
    Older End-of-Day Signals for RLMD ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 1 hour ago
    60 Minute Opening Range Breakdown about 4 hours ago
    Down 2 % about 4 hours ago
    Up 2% about 5 hours ago
    3x Volume Pace about 5 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    RLMD Chart by TradingView
    Basic chart:

    Profile

    Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, dextromethadone (REL-1017), is an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor antagonists may have potential in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.
    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Biotechnology Disease Neuroscience Neurological Disorders Urological Disorders Neurochemistry Glutamate Drug Rehabilitation Neurotransmitters Psychiatric And Neurological Disorders N Methyl D Aspartic Acid Nmda Receptor Antagonists

    Is RLMD a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 19 Relmada Therapeutics to Present at Jefferies London Healthcare Conference
    Nov 14 Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
    Nov 11 Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024
    Nov 10 Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript
    Nov 8 Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ...
    Nov 7 Relmada Therapeutics GAAP EPS of -$0.72 misses by $0.08
    Nov 7 Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
    Nov 4 Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
    Oct 22 3 US Penny Stocks To Monitor In October 2024
    Sep 17 Relmada jumps as Jefferies upgrades on a potential turnaround story
    See more RLMD news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.2225
    52 Week Low 1.88
    Average Volume 202,176
    200-Day Moving Average 3.80
    50-Day Moving Average 3.37
    20-Day Moving Average 3.32
    10-Day Moving Average 3.13
    Average True Range 0.22
    RSI (14) 25.93
    ADX 17.7
    +DI 12.45
    -DI 27.30
    Chandelier Exit (Long, 3 ATRs) 3.33
    Chandelier Exit (Short, 3 ATRs) 3.46
    Upper Bollinger Bands 3.77
    Lower Bollinger Band 2.87
    Percent B (%b) -0.02
    BandWidth 27.28
    MACD Line -0.12
    MACD Signal Line -0.06
    MACD Histogram -0.06
    Fundamentals Value
    Market Cap 85.78 Million
    Num Shares 30.1 Million
    EPS -3.71
    Price-to-Earnings (P/E) Ratio -0.77
    Price-to-Sales 0.00
    Price-to-Book 1.63
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.20
    Resistance 3 (R3) 3.22 3.13 3.14
    Resistance 2 (R2) 3.13 3.04 3.12 3.12
    Resistance 1 (R1) 2.99 2.99 2.95 2.97 3.10
    Pivot Point 2.90 2.90 2.88 2.89 2.90
    Support 1 (S1) 2.76 2.81 2.72 2.74 2.60
    Support 2 (S2) 2.67 2.76 2.66 2.58
    Support 3 (S3) 2.53 2.67 2.56
    Support 4 (S4) 2.51